Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Down Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable